𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ineffectiveness of deanol in tardive dyskinesia: A placebo controlled study

✍ Scribed by C. Montigny; G. Chouinard; L. Annable

Publisher
Springer
Year
1979
Tongue
English
Weight
536 KB
Volume
65
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

✦ Synopsis

In a double-blind placebo-controlled study, deanol acetamidobenzoate, administered in doses up to 1.5 g q.d. for three weeks to chronic schizophrenic patients presenting moderate to severe tardive dyskinesia, failed to alleviate the dyskinetic movements. However, there was a tendency for a significant increase in the schizophrenic symptoms of the deanol-treated group relative to the control group. The ineffectiveness of deanol in alleviating tardive dyskinesia is consistent with its inability to enhance brain acetylcholine synthesis. The worsening of the schizophrenic symptoms may possibly result from an interference by deanol with central cholinergic function.

📜 SIMILAR VOLUMES

A pilot study of verapamil in the treatm
A pilot study of verapamil in the treatment of tardive dyskinesia
✍ Timothy G. Dinan; Claire Capstick 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB 👁 1 views

Six patients with severe and stable tardive dyskinesia were treated with verapamil, a calcium channel blocker, in doses ranging from 240 to 400 mg/day. Weekly assessments were made using the Simpson tardive dyskinesia rating scale. Neuroleptic medication was held constant during the 3-month baseline

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
✍ Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Pet 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

## Abstract ## Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s

Hypericum treatment of mild–moderate dep
Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study
✍ E. Schrader; B. Meier; A. Brattström 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

A prospective, randomized, multicentre, double-blind placebo controlled study is described which compares the ecacy and tolerability of hypericum administered as a concentrated ethanolic extract of St John's wort (ZE117) to patients with mild±moderate depression (ICD-10; F 32 . 0 mild; F 32 . 1 mode